D-0926-2018 Class I Terminated

Recalled by AuroMedics Pharma LLC — East Windsor, NJ

FDA drug recall D-0926-2018 was initiated by AuroMedics Pharma LLC on May 1, 2018 and is designated Class I. Reason for recall: Presence of Particulate Matter: confirmed customer report for presence of visible particulate matter, confirmed as glass The recall status is terminated (terminated Jun 21, 2023). Affected quantity: 77,400 vials.

Recall Details

Product Type
Drugs
Report Date
May 23, 2018
Initiation Date
May 1, 2018
Termination Date
Jun 21, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
77,400 vials

Product Description

Piperacillin and Tazobactam for Injection, USP 3.375 grams per vial, For Intravenous Use Only, Single-Dose vial, Rx Only, Manufactured for: AuroMedics Pharma LLC, 6 Wheeling Road, Dayton, NJ 05610. NDC 55150-120-30

Reason for Recall

Presence of Particulate Matter: confirmed customer report for presence of visible particulate matter, confirmed as glass

Distribution Pattern

Nationwide in the USA

Code Information

Lot #s: PP0317061-A, PP0317049-A; EXP August 2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0926-2018
openFDA file date
Oct 6, 2026
Loaded by RegDataLab
Oct 12, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it. FDA may have changed the recall since.